Alx Oncology Holdings Inc (ALXO) concluded trading on Thursday at a closing price of $1.31, with 13.63 million shares of worth about $17.86 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.79% during that period and on March 06, 2025 the price saw a gain of about 25.96%. Currently the company’s common shares owned by public are about 52.74M shares, out of which, 33.63M shares are available for trading.
Stock saw a price change of 22.43% in past 5 days and over the past one month there was a price change of 1.55%. Year-to-date (YTD), ALXO shares are showing a performance of -21.56% which decreased to -91.09% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.95 but also hit the highest price of $17.83 during that period. The average intraday trading volume for Alx Oncology Holdings Inc shares is 1.03 million. The stock is currently trading 19.31% above its 20-day simple moving average (SMA20), while that difference is down -7.22% for SMA50 and it goes to -60.88% lower than SMA200.
Alx Oncology Holdings Inc (NASDAQ: ALXO) currently have 52.74M outstanding shares and institutions hold larger chunk of about 56.98% of that.
The stock has a current market capitalization of $69.09M and its 3Y-monthly beta is at 1.01. It has posted earnings per share of -$2.98 in the same period. It has Quick Ratio of 4.82 while making debt-to-equity ratio of 0.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALXO, volatility over the week remained 14.80% while standing at 9.55% over the month.
Stock’s fiscal year EPS is expected to rise by 26.31% while it is estimated to increase by 10.38% in next year. EPS is likely to grow at an annualized rate of 18.87% for next 5-years, compared to annual growth of -50.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on Mar-07-25 offering a Buy rating for the stock and assigned a target price range of between $2 and $3 to it. Coverage by Jefferies stated Alx Oncology Holdings Inc (ALXO) stock as a Hold in their note to investors on December 19, 2024, suggesting a price target of $2 for the stock. On March 08, 2024, Stifel Downgrade their recommendations, while on December 08, 2023, Jefferies Upgrade their ratings for the stock with a price target of $18. Stock get a Hold rating from Jefferies on December 22, 2021.
